September 21, 2020 -- Integral Molecular was awarded over $520,000 from the state of Pennsylvania to leverage its technologies in COVID-19 research. The grant will enable the company and its partners to develop therapies and vaccines against SARS-CoV-2.
Four of Integral Molecular's technology platforms are being used in the fight against the virus, including:
- MPS Antibody Discovery platform to generate reactive antibodies against SARS-CoV-2 and other coronaviruses
- SARS-CoV-2 reporter virus particles (RVPs) to test the safety for neutralizing immune responses in patients and vaccines
- Membrane protein array (MPA) to rapidly screen for specificity of antibodies for SARS-CoV-2
- Shotgun mutagenesis epitope mapping to optimize vaccine and antibody design
The funding was received through the state's COVID-19 Vaccines, Treatments, and Therapies (CV-VTT) program.
Copyright © 2020 scienceboard.net